Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug
Abbisko Doses First Gastric Cancer Patient in Phase II Study of Solid Tumor Drug
Abbisko在固體腫瘤藥物的二期研究中爲首位胃癌患者給藥。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間